Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced the results of its 2009 Annual Meeting of Stockholders. At the meeting, held earlier today, stockholders elected the following persons to Noven’s Board of Directors:
Peter Brandt – Noven’s President and CEO; John G. Clarkson, M.D. – Executive Director of the American Board of Ophthalmology and Dean Emeritus and Professor of Ophthalmology, University of Miami Miller School of Medicine; Donald A. Denkhaus – Executive Chairman, TM Systems, LLC and former partner with Arthur Andersen LLP; Pedro P. Granadillo – Former Senior Vice President – Global Manufacturing and Human Resources, Eli Lilly & Company; Phillip M. Satow – Former CEO and co-founder of JDS Pharmaceuticals, LLC; Robert G. Savage – Former Worldwide Chairman, Pharmaceuticals Group, Johnson & Johnson; and Wayne P. Yetter – Former CEO, Verispan LLC, and non-executive Chairman of the Board of Noven.
Stockholders also approved Noven’s 2009 Equity Incentive Plan and ratified the appointment of Deloitte & Touche LLP as Noven’s independent registered public accounting firm for 2009. At the meeting, Peter Brandt provided an update on Noven’s business and prospects,
No comments:
Post a Comment